能否从治疗前SSTR PET预测177Lu-DOTATATE肾脏吸收剂量?多中心数据发现
各中心肾脏SSTR PET摄取与吸收剂量均显著相关(决定系数0.14–0.53),汇总混合效应模型决定系数0.25(P<0.01),外部验证平均相对绝对误差28%,内部验证22%。作者认为相关性虽显著但中等,中心间差异提示需标准化显像方案与剂量学流程。
要点
- 汇总混合效应模型决定系数0.25(P<0.01),外部验证平均相对绝对误差28%,内部验证22%。
- 各中心间吸收剂量与PET摄取的均值差异均有统计学意义(单因素方差分析P<0.0001),作者提示需标准化显像与剂量学流程。
核心结论
- 多中心人群中肾脏SSTR PET摄取与177Lu-DOTATATE肾脏吸收剂量的相关性有统计学意义但仅为中等。
- 预测模型在外部与内部验证中平均相对绝对误差均不超过28%。
- 中心间差异提示需要标准化的显像方案和剂量学工作流程。
研究设计与样本
- 回顾性研究,纳入5个中心的数据:加拿大1个中心(n=25)、挪威1个中心(n=75)、瑞典1个中心(n=18)、美国2个中心(n=36和n=26)。
- 各中心按本机构方案进行治疗前SSTR PET/CT显像和第一周期177Lu显像的剂量学计算。
- 以基线SSTR PET肾脏摄取值建立混合效应模型(中心作为随机效应)预测177Lu-DOTATATE肾脏吸收剂量,并行留一中心交叉验证(外部验证)和留一样本交叉验证(内部验证),评价平均绝对误差和平均相对绝对误差。
主要发现
- 全部中心第一周期肾脏吸收剂量中位数为0.56 Gy/GBq(范围0.14–1.27 Gy/GBq),治疗前SSTR PET肾脏摄取中位数为110.7 Bq/mL/MBq(范围28.6–287.7 Bq/mL/MBq)。
- 各中心间吸收剂量与PET摄取的均值差异均有统计学意义(单因素方差分析P<0.0001)。
- 各中心肾脏SSTR PET摄取与177Lu-DOTATATE吸收剂量均显著相关(P<0.05),中心特异性决定系数范围为0.14–0.53。
- 汇总所有中心数据后,混合效应模型决定系数为0.25(P<0.01)。
- 外部验证平均绝对误差0.15 Gy/GBq(标准差0.11 Gy/GBq)、平均相对绝对误差28%(标准差24%);内部验证分别为0.12 Gy/GBq(标准差0.10 Gy/GBq)和22%(标准差20%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Before performing 177Lu-DOTATATE therapy for neuroendocrine tumors, somatostatin receptor (SSTR) PET imaging is currently used to confirm sufficient tumor SSTR expression, but it also has potential to be used to personalize treatment by predicting absorbed doses to critical organs. This study aims to validate the predictive capability of SSTR PET in anticipating renal absorbed dose in the first cycle of 177Lu-DOTATATE using a multicenter dataset to analyze and derive insights from a broader patient population. Methods: Retrospective data from 5 centers were included in this study: 1 in Canada (n = 25), 1 in Norway (n = 75), 1 in Sweden (n = 18), and 2 in the United States (n = 36 and n = 26). At each center, pretherapy SSTR PET/CT imaging and postcycle 1 177Lu imaging-based dosimetry were performed according to site-specific protocols. The mixed-effects model treating centers as random effects was developed using baseline SSTR PET renal uptake values to predict renal absorbed dose from 177Lu-DOTATATE. Additionally, leave-one-center-out cross-validation and leave-one-sample-out cross-validation were implemented for external and internal validation, respectively, measuring mean absolute error and mean relative absolute error. Results: Across all participating centers, the median cycle 1 renal absorbed dose was 0.56 Gy/GBq (range, 0.14-1.27 Gy/GBq), whereas the median pretherapy SSTR PET renal uptake was 110.7 Bq/mL/MBq (range, 28.6-287.7 Bq/mL/MBq). The differences among center means were statistically significant for both absorbed dose and PET uptake (P < 0.0001 from 1-way ANOVA). A significant (P < 0.05) correlation was observed between kidney SSTR PET uptake and 177Lu-DOTATATE absorbed dose for each center (center-specific coefficient of determination ranged from 0.14 to 0.53). When data across all centers were aggregated, the mixed-effects model achieved a coefficient of determination of 0.25 (P < 0.01), resulting in an mean absolute error of 0.15 Gy/GBq (SD, 0.11 Gy/GBq) and an mean relative absolute error of 28% (SD, 24%) for external validation and 0.12 Gy/GBq (SD, 0.10 Gy/GBq) and 22% (SD, 20%) for internal validation. Conclusion: The correlations observed between SSTR PET renal uptake and 177Lu-DOTATATE absorbed dose to kidneys across a multicenter population are statistically significant yet modest. The prediction model achieved a mean relative absolute error 28% or less for both external and internal validation of PET-predicted absorbed doses. The intercenter differences suggest the need for standardized imaging protocols and dosimetry workflows.
引用
- Akhavanallaf A, Lu Z, Peterson AB, et al. Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data. J Nucl Med. 2025. PMID: 40404396. doi:10.2967/jnumed.124.269098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。